Oneness & Microbio (Shanghai) host an international press conference to present the pan-COVID new drug, SNS812 Phase 2 clinical trial results and future prospects

Published Date:2024-09-08

Original Link:https://www.onenessbio.com/en/news_detail318_1.htm

Statement
No	2	Date of announcement	2024/09/08	Time of announcement	18:18:59
Subject	Oneness & Microbio (Shanghai) host an international press conference to present the pan-COVID new drug, SNS812 Phase 2 clinical trial results and future prospects
To which item it meets	paragraph 53			Date of events	2024/09/08
Date of occurrence of the event: 2024/09/08 Company name: ONENESS BIOTECH CO., LTD. Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office Reciprocal shareholding ratios: NA Cause of occurrence: (1) The Phase 2 clinical trial data of SNS812, the pan-COVID new drug co-developed by Oneness and Microbio (Shanghai) has been unblinded and showed statistical significance in the endpoints. For future international cooperation and the global make access, an international press conference will be held at 3:30 PM on September 9, 2024, at the Grand Hyatt Taipei, Grand ballroom (3rd Floor, No.2 Songshou Road, Xinyi District, Taipei). The press conference will be live-streaming online and will provide details on the results of the SNS812 Phase 2 trial and future prospects. (2) The press conference will be jointly hosted by Dr. Shu-ling Cheng, President of Oneness Biotech and Dr. Yi-Chung Chang, President of Microbio (Shanghai) and joined by Prof. Pan-Chyr Yang, M.D., Ph.D., the Chief Scientific Advisor of Oneness Biotech and the Academia Sinica Academician, Prof. Shey-Ying Chen, M.D., Ph.D., the lead principal investigator of SNS812 Phase 2 study and the Department of Emergency Medicine at NTU, Prof. Sui-Yuan Chang, Ph.D., the virologist and Department of Clinical Laboratory Science and Medical Biotechnology at NTU. They will provide an overview of the global COVID-19 status quo, SNS812 clinical data, and virus analysis results. Countermeasures: None Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): (1) The press conference will be live-streaming online at 3:30 PM via below link: YouTube(Mandarin): https://youtube.com/live/hoHnQZBtWRE?feature=share YouTube(English): https://youtube.com/live/7xKjUbhEL3M?feature=share e (2) The presentation materials and video recordings will be made publicly available on our company’s website after the event.e